Purple Biotech (PPBT) Notes Payables (2014 - 2018)

Purple Biotech (PPBT) has reported Notes Payables for 5 consecutive years, with $554000.0 the latest figure, recorded in Q4 2018.

• On a quarterly basis, Notes Payables fell 72.47% year-over-year to $554000.0 in Q4 2018; TTM through Dec 2018 was $554000.0, a 72.47% decrease from a year earlier, with the FY2018 full-year figure at $554000.0, down 72.47% from the prior year.
• Notes Payables was $554000.0 for Q4 2018 at Purple Biotech, down from $4.3 million in the prior quarter.
• Over five years, Notes Payables peaked at $4.3 million in Q2 2018 and troughed at $78000.0 in Q4 2014.
• A 5-year average of $992725.0 and a median of $354500.0 in 2014 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables surged 1450.08% in 2017 and tumbled 72.47% in 2018, its largest moves.
• Over 5 years, Notes Payables stood at $78000.0 in 2014, then soared by 80.77% to $141000.0 in 2015, then slipped by 7.94% to $129800.0 in 2016, then surged by 1450.08% to $2.0 million in 2017, then plunged by 72.47% to $554000.0 in 2018.
• The last three Notes Payables figures came in at $554000.0 (Q4 2018), $4.3 million (Q2 2018), and $2.0 million (Q4 2017), per Business Quant data.